HCW Biologics Advances TGF-β/IL-15 Cancer Immunotherapy
Miramar, Fla. – August 25, 2026 HCW Biologics announced new findings supporting its TGF-β trap and IL-15 fusion moiety...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Miramar, Fla. – August 25, 2026 HCW Biologics announced new findings supporting its TGF-β trap and IL-15 fusion moiety...
SHANGHAI and HONG KONG, China, June 8, 2026 Antengene Corporation Limited announced the presentation of the first preclinical data...
BOSTON, Mass., Feb. 20, 2026 — New clinical findings presented at a major oncology symposium demonstrate that ficerafusp alfa...
